Adapting Gastrointestinal Organoids for Pathogen Infection and Single Cell Sequencing under Biosafety Level 3 (BSL-3) Conditions
September 10th, 2021
6K views
This protocol describes how to infect human intestinal organoids from either their apical or basolateral side to characterize host/pathogen interactions at the single-cell level using single-cell RNA sequencing (scRNAseq) technology.
Overview
This protocol describes methods to infect human intestinal organoids to study host/pathogen interactions at the single-cell level using single-cell RNA sequencing (scRNAseq). It emphasizes the importance of using fully differentiated organoids and adhering to biosafety regulations when working with pathogens.
Key Study Components
Area of Science
- Neuroscience
- Microbiology
- Cell Biology
Background
- Understanding viral infections in human intestinal epithelium is crucial for developing therapeutic strategies.
- Human intestinal organoids serve as a model to study these interactions.
- Single-cell RNA sequencing allows for detailed analysis of cellular responses.
- Proper handling of Category 3 pathogens is essential for safety and accuracy.
Purpose of Study
- To characterize the response of individual cell types in human intestinal organoids to viral infections.
- To investigate how the route of infection affects cellular responses.
- To adapt the protocol for various pathogens and organoid cultures.
Methods Used
- Infection of organoids from apical or basolateral sides.
- Preparation of samples for single-cell RNA sequencing.
- Isolation of single cells from infected organoids.
- Analysis of immune responses and viral infection dynamics.
Main Results
- Only a subpopulation of intestinal epithelial cells supported SARS-CoV-2 infection.
- Infected cells exhibited a pro-inflammatory response, while non-infected cells showed an interferon-mediated response.
- Infected cells were unable to sense interferons due to viral interference.
- Organoid differentiation and health are critical for successful experiments.
Conclusions
- This protocol provides a framework for studying viral infections in human intestinal organoids.
- Findings highlight the complexity of host-pathogen interactions at the single-cell level.
- Future studies can leverage this method to explore other pathogens.
Frequently Asked Questions
What are human intestinal organoids?
Human intestinal organoids are 3D structures derived from stem cells that mimic the architecture and function of the human intestine.
Why is single-cell RNA sequencing important?
Single-cell RNA sequencing allows researchers to analyze gene expression at the individual cell level, providing insights into cellular heterogeneity and responses.
What safety measures are necessary when working with Category 3 pathogens?
Biosafety regulations must be followed, including using appropriate personal protective equipment and working in designated biosafety cabinets.
How can this protocol be adapted for other pathogens?
The methods described can be modified based on the specific characteristics of the pathogen and the organoid culture conditions.
What are the key considerations for organoid health?
Ensuring that organoids are fully differentiated and maintained under optimal culture conditions is crucial for successful experiments.
What cellular responses were observed in SARS-CoV-2 infected organoids?
Infected organoids showed a pro-inflammatory response, while non-infected cells exhibited an interferon-mediated immune response.
Executive Industry Relevance
This protocol enables biopharma R&D teams to model human gastrointestinal pathogen interactions under BSL-3 conditions, supporting target validation and mechanistic de-risking for antiviral therapeutics. By linking infection route to single-cell transcriptional responses, it provides predictive confidence in cell-type-specific tropism and host-pathogen mechanisms. The approach supports early discovery decisions by identifying which intestinal cell subtypes are permissive to infection and how they respond immunologically.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by identifying which specific intestinal epithelial cell types support viral infection.
- Operational Value: Supports biological de-risking through precise mapping of pathogen tropism across GI tract regions and differentiation states.
- Predictive Value: Enhances target confidence by revealing subpopulations of cells that drive infection and immune evasion, such as interferon sensing blockade.
Screening & Assay Development
- Scientific Value: Prepares validated, differentiated organoid systems for reliable compound screening against enteric pathogens.
- Operational Value: Standardizes infection workflows (apical vs. basolateral) and single-cell dissociation under containment, improving reproducibility.
- Scalability: Enables platform reuse across pathogens and organoid types (colon, ileum, etc.) with consistent scRNAseq-ready outputs.
Translational & Preclinical Research
- Translational Continuity: Maintains disease-relevant modeling from discovery through preclinical validation by preserving GI tract architecture and cellular complexity.
- Mechanistic De-risking: Links viral infection to cell-type-specific innate immune responses, informing biomarker selection and safety assessment.
- Risk-Adjusted Advancement: Supports go/no-go decisions by identifying bystander cell responses (e.g., interferon signaling) that may predict therapeutic windows or immunopathology.
Pipeline & Workflow Integration
The method integrates into early discovery workflows by enabling hypothesis-driven infection studies that feed into lead identification and preclinical evaluation through mechanistic insights.
- Discovery Biology: Supports hypothesis testing of viral entry, replication, and immune modulation in defined intestinal cell types.
- Screening: Delivers quantitative, single-cell resolution readouts essential for comparing compound effects across infection conditions.
- Analytics: Generates scRNAseq data that reveal transcriptional states, immune signaling, and viral host shutoff mechanisms.
- Translational Research: Connects organoid models to preclinical continuity by maintaining differentiation markers and tissue-specific responses.
- Enterprise Reuse: Establishes a reusable BSL-3-compliant platform for studying diverse enteric pathogens across multiple GI tract models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through cell-type-specific infection and response profiling.
- Operational Value: Standardization, reproducibility, and biosafety-compliant processing of 3D organoids for downstream genomics.
- Strategic Value: Improved go/no-go decisions by de-risking mechanistic ambiguity in host-pathogen interactions.
- Portfolio Impact: Enables risk-adjusted prioritization of antiviral candidates based on epithelial cell tropism and immune activation profiles.
Implementation Considerations
- Requires expertise in organoid culture, viral handling under BSL-3, and single-cell genomics workflows.
- Dependent on access to BSL-3 facilities, dissociation enzymes, and scRNAseq platforms compatible with infected samples.
- Necessitates cross-team standardization between virology, stem cell, and bioinformatics groups for consistent organoid preparation and infection timing.
- Requires adaptation of infection parameters (MOI, timepoints) across pathogen and organoid model systems.
- Dependent on organoid maturity and health, which must be confirmed via differentiation markers prior to infection to ensure data interpretability.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in organoid infection models?
Null hypothesis testing helps determine whether observed infection in specific intestinal cell types is statistically significant rather than due to random variation, supporting confident target selection. This is critical when only a subpopulation of cells, as seen with SARS-CoV-2 in colon and ileum organoids, supports viral replication.
How does isolating the infection route (apical vs. basolateral) as an independent variable fit the discovery pipeline?
By treating infection route as an independent variable, researchers can mechanistically de-risk hypotheses about viral entry preferences and cell-type-specific responses, which informs target validation and assay design. This approach was used to compare how luminal versus tissue-side exposure influences host-pathogen interactions in differentiated organoids.
What quantitative dependent variable measurements from single-cell RNA sequencing enable target de-risking?
scRNAseq provides quantitative measurements such as gene expression levels, viral transcript counts, and immune pathway activation scores per cell, enabling precise characterization of heterogeneous responses. These metrics allowed identification of infected cells with pro-inflammatory signaling and bystander cells with interferon-mediated responses in SARS-CoV-2-infected organoids.
Why do replication requirements across organoid batches matter for cross-functional collaboration?
Replication ensures that observed infection patterns and transcriptional responses are consistent and not artifacts of batch-specific organoid variability, which is essential for reliable data sharing between biology and computational teams. Consistent differentiation and infection rates across batches support trust in scRNAseq outputs used for target prioritization.
What statistical analysis capabilities are required before implementing this organoid infection and scRNAseq workflow?
Teams must be able to perform differential expression analysis, cell clustering, and trajectory inference to link infection status with transcriptional states and immune responses. These capabilities were used to detect interferon sensing blockade in infected cells and distinct bystander signaling in SARS-CoV-2-infected intestinal organoids.
Chapters in this video
0:04
Introduction
1:04
Preparation of Single-Cell Solution and Preparation of Gel Beads-in-Emulsion Under Biosafety Level 3 Conditions
5:47
Results: Characterization of Host/Pathogen Interactions at a Single-Cell Level Using scRNAseq Technology
7:11
Conclusion
